Cor Vasa 2006, 48(11):373-375 | DOI: 10.33678/cor.2006.121

Vazodilatační léčba aneb 20 let klinických studií srdečního selhání

Jiří Vítovec
I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

Published: November 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J. Vazodilatační léčba aneb 20 let klinických studií srdečního selhání. Cor Vasa. 2006;48(11):373-375. doi: 10.33678/cor.2006.121.
Download citation

References

  1. Widimský J. Klady a úskalí "evidence based" medicíny. Cor Vasa 2006;48:24-31. Go to original source...
  2. ©pinar J. Co nám říkají klinické studie s negativním a neutrálním závěrem? Cor Vasa 2006;48:168-71. Go to original source...
  3. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HEFT I). New Engl J Med 1986;314: 1547-52. Go to original source... Go to PubMed...
  4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine. Isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HEFT II). New Engl J Med 1991;325:303-10. Go to original source... Go to PubMed...
  5. Carson P, Ziesche S, Johnson G, Cohn JN. Vasodilator-Heart Failure Trial Study Workgroup. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trial. Card Fail 1999;5: 178-87. Go to original source... Go to PubMed...
  6. Taylor AL, Ziesche S, Yancy C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure (A-HEFT). New Engl J Med 2004;351: 2049-57. Go to original source... Go to PubMed...
  7. Massie B, Chatterjee K, Werner J, et al. Hemodynamic advantage for combined administration of hydralazin orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 1977;40: 794-801. Go to original source... Go to PubMed...
  8. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-8. Go to original source... Go to PubMed...
  9. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26:1115-40. Go to original source... Go to PubMed...
  10. Cooper RS, Kaufman JS, Ward R. Race and genomics. New Engl J Med 2003;348:1166-70. Go to original source... Go to PubMed...
  11. Haga SB, Ginsburg GS. Prescribing BiDil: Is It Black and White? J Am Coll Cardiol 2006;48:12-4. Go to original source... Go to PubMed...
  12. Cohn JN. Efficacy and Safety in Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol 2006;48:430-3. Go to original source... Go to PubMed...
  13. Vítovec J. Hemodynamika vazodilatační léčby srdečního selhání. Kandidátská disertační práce. Brno: UJEP, 1988:118.




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.